Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
NEW BRUNSWICK, NJ, May 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.No clinical studies in hepatitis B have been initiated by Janssen ut...
Source: Johnson and Johnson - May 9, 2022 Category: Pharmaceuticals Source Type: news
Hope for cancer patients
University of Edinburgh researchers discovered the test, known as a liquid biopsy, can accurately predict if cancer caused by human papillomavirus (HPV) is going to come back. (Source: the Mail online | Health)
Source: the Mail online | Health - May 1, 2022 Category: Consumer Health News Source Type: news
Science Saturday: Uncovering disparities in local communities -- the case of the HPV vaccine
Where you live may affect whether you receive the cancer-preventing HPV vaccine, suggests a new study published in the journal Vaccine. The first human papillomavirus (HPV) vaccine was approved for use in the U.S. by the Food and Drug Administration in 2006. According to the National Cancer Institute, the types of HPV the current vaccine covers are those which cause 90% of genital warts, as many as 90% of cervical cancers, as well as a majority of oropharyngeal (a type of throat cancer), anal, penile, vaginal and vulvar cancers.… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - April 30, 2022 Category: Research Source Type: news
HPV: High-risk infections could trigger a cancerous tumour – what to look out for
HPV CAN be a dangerous infection, depending on which strain you come in contact with. Some human papillomavirus infections cause cell changes that can lead to cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - April 21, 2022 Category: Consumer Health News Source Type: news
Cervical cancer screening and prevention among survivors of intimate partner violence - Bagwell-Gray ME, Ramaswamy M.
Women who experience intimate partner violence are an underserved population at risk for cervical cancer, precipitated by their heightened risk for human papilloma virus (HPV) and underutilization of gynecological care. This pilot study describes the self-... (Source: SafetyLit)
Source: SafetyLit - March 24, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
HPV Vaccination May Be Cutting Cervical Cancer Rates
WEDNESDAY, March 16, 2022 -- The recent decrease in the incidence of cervical cancers, particularly in young women, may be associated with human papillomavirus (HPV) vaccination approval, according to a study published online March 16 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 16, 2022 Category: Pharmaceuticals Source Type: news
HPV-Associated Cancer Incidence Starting to Increase
FRIDAY, March 11, 2022 -- The incidence of human papillomavirus (HPV)-associated cancers is beginning to increase, with greater increases seen in the lowest-income counties and in counties with high smoking prevalence, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Poll: Many Teens Don't Realize STD Risks From Oral Sex
Oral sex can transmit herpes, gonorrhea, chlamydia, syphilis, HIV and human papillomavirus (HPV), which can lead to cervical cancer, and head and neck cancers. (Source: WebMD Health)
Source: WebMD Health - February 2, 2022 Category: Consumer Health News Source Type: news
Menstrual Blood Sequencing Effective for HPV Screening Menstrual Blood Sequencing Effective for HPV Screening
Screening for human papillomavirus in high-risk individuals may be done effectively and noninvasively using menstrual blood testing with target-capture sequencing, a clinical study suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 26, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news
Ethiopia: Ethiopia to Immunize Over 1.8 Million Girls Against Human Papillomavirus
[WHO-AFRO] Addis Ababa -- A human papillomavirus (HPV) vaccination campaign that aims to immunize over 1.8 million 14-year-old girls in nine regions against HPV is underway. The campaign commenced on 10 January 2022 and will end on 22 January. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 23, 2022 Category: African Health Source Type: news
Nigeria: Niger State Govt Begins Cervical Cancer Services in Line With WHO's Recommendation
[WHO-AFRO] In line with the World Health Organization's (WHO) recommendation for screening and treatment to prevent cervical cancer, the Niger State Government has begun screening women for Human Papillomavirus (HPV) and cancer prevention services in nine Local Government Areas (LGA). (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 21, 2022 Category: African Health Source Type: news
Covax, the Developing World ’ s Hope against COVID, Has Made It Only Halfway
Delivery of syringes for the vaccination campaign in El Salvador. Latin American countries have made steady progress in immunizing their populations, partly through direct negotiations between their governments and suppliers and partly through international cooperation. CREDIT: PAHO
By Humberto MárquezCARACAS, Jan 20 2022 (IPS) The Covax initiative, the hope of the countries of the developing South to immunize their populations against COVID-19, only met half of its goals in 2021. And as 2022 begins, and the omicron variant of the virus is spreading fast, the scheme still depends on the decisions of pharmaceutical compani...
Source: IPS Inter Press Service - Health - January 20, 2022 Category: International Medicine & Public Health Authors: Humberto Marquez Tags: COVID-19 Development & Aid Editors' Choice Featured Global Global Governance Headlines Health Humanitarian Emergencies Regional Categories TerraViva United Nations COVAX COVID-19 vaccines Source Type: news
UofL researchers reveal how oral bacteria suppress protection against viral growth
Bacteria that cause periodontal disease reduce oral defense and increase viral growth By Betty Coffman LOUISVILLE, Ky. – Researchers from the University of Louisville School of Dentistry and their colleagues have discovered details of how proteins produced by oral epithelial cells protect humans against viruses entering the body through the mouth. They also found that oral bacteria can suppress the activity of the se cells, increasing vulnerability to infection. A family of proteins known as interferon lambdas produced by epithelial cells in the mouth serve to protect humans from viral infection, but...
Source: Dental Technology Blog - January 6, 2022 Category: Dentistry Source Type: news
